NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Multivariate analyses reveal that pathologic complete response is associated with transcriptomic differences and chemotherapy type, rather than self-reported race IRVINE, Calif., and AMSTERDAM, May 1, 2026 — Agendia®, Inc., a leader in precision oncology Read More
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics IRVINE, Calif. & AMSTERDAM--Agendia®, Inc., a leader in precision oncology for breast cancer, Read More
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes IRVINE, Calif., and AMSTERDAM — March Read More
Newsroom
News, Stories & Breast Cancer Blog
Health Rounds: Genomic Testing Improves Treatment, Survival for Black Breast Cancer Patients
Advanced genomic testing could help erase significant disparities in breast cancer survival rates between white and Black patients, new research has found. Currently, Black women in the U.S. have a 40% higher breast cancer mortality Read More
Genomic Testing Finds a Higher Prevalence of High-Risk Breast Cancer in Black Women
These findings highlight the critical need for tumor genomic testing for all patients to identify those with high-risk tumors, which occur more frequently in Black women, and which require more aggressive treatment to prevent Read More
Industry Insights Interview: Genomic Testing for Early-Stage Breast Cancer
William Audeh, Chief Medical Officer at Agendia, discusses recent data supporting genomic testing results in guiding clinical decision-making How have genomic assays transformed decision-making for early-stage breast cancer, particularly in determining whether patients benefit from Read More
Anthracycline Chemotherapy Benefit in HR+/HER2− Early-Stage Breast Cancer Treatment
After a diagnosis of early-stage hormone receptor–positive (HR+) and HER2-negative (HER2–) breast cancer, conversations with your oncology team about treatment options may include whether chemotherapy should be part of your care. One of the Read More
Understanding Risk of Recurrence in Breast Cancer
Hearing the words “You have breast cancer” can change everything in an instant. It’s an overwhelming moment—filled with uncertainty, hope, and countless decisions about surgery, chemotherapy, radiation, and recovery. Yet, even after treatment ends, a single, Read More
For Breast Cancer Patients, Genomic Tests Enable Personalized Treatment Options
Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make personalized care decisions. For the more than 300,000 women diagnosed with breast cancer Read More
Early Breast Cancer: Personalizing Chemotherapy Decisions
Using real-world data from the FLEX registry, MammaPrint, a 70-gene signature for risk of distant recurrence, was found to be predictive of chemotherapy benefit and distant recurrence-free interval prognosis in early-stage breast cancer. Read More
